跳至主要内容
临床试验/2024-519067-17-00
2024-519067-17-00招募中2 期

Prospective phase IIb study to evaluate the efficacy of laparoscopic electrochemotherapy in the treatment of locally advanced pancreatic cancer - ECT-LAPC Laparoscopic

IRCCS Istituto Nazionale Tumori Fondazione Pascale5 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2024年12月2日最近更新:
相关药物

试验速览

阶段
2 期
状态
招募中
入组人数
90
试验地点
5
主要终点
Increase in the objective response rate of the treated lesion in the treatment arm compared to the control arm

研究概览

简要总结

The aim of the study is to evaluate the efficacy of electrochemotherapy followed by conventional systemic treatment compared to the only systemic treatment in LAPC in terms of objective response. The use of ECT and IRE, in deep cancer e.g. liver and pancreas, currently requires a laparotomy surgical approach and limits its applicability due to the risks associated with open surgery. In our study a new generation of electrodes suitable to treat tumor nodules with ECT with a minimally invasive approach, i.e. laparoscopic surgery, will be used.

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 65+ years(65+ Years, 18-64 Years)
接受健康志愿者

入选标准

  • Age≥ 18 years
  • Good mental health conditions
  • Ability to sign a specific informed consent in order to be enrolled to the study.
  • Life expectancy in line with the follow-up indicated by the study
  • Diagnosis of exocrine pancreatic cancer with histological confirmation
  • Preoperative Staging of locally advanced pancreatic cancer disease: stage III
  • The subject is not eligible for the "gold-standard" treatment of surgical pancreatectomy and is eligible for a conventional systemic treatment (FOLFOXIRI)

排除标准

  • Age less than 18 years
  • Contraindications at the assumption of bleomycin (Bleoprim)
  • Previous allergic reactions to bleomycin
  • Previous cumulative dose of 250 mg/m2 of bleomycin exceeded
  • Pregnancy or lactation
  • Absolute contraindication to surgery
  • Visceral, bone or diffuse metastases
  • Presence of extrahepatic spread of the disease
  • Clinically significant ascites
  • Any serious and uncontrolled systemic illness
  • Acute lung infection
  • Symptoms of poor lung function by clinical examination and Pulmonary function tests (PFT)
  • Non correctable severe coagulation disorders

结局指标

主要结局

Increase in the objective response rate of the treated lesion in the treatment arm compared to the control arm

Increase in the objective response rate of the treated lesion in the treatment arm compared to the control arm

次要结局

  • Evaluate the effect of ECT on disease progression-free time and survival.
  • Evaluate the impact of ECT on quality of life, with particular attention to its effect on pain
  • Assess the toxicity associated with Electrochemotherapy treatment.
  • Evaluate the conversion rate of the disease from locally advanced to resectable between the two arms.

研究者

申办方类型
Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

Francesco Izzo

Scientific

IRCCS Istituto Nazionale Tumori Fondazione Pascale

研究点 (5)

Loading locations...

相似试验

进行中(未招募)
1 期
Clinical trial to evaluate the efficacy and the safety of a combination of bendamustine-melphalan as preparative regimen to autologous transplantation of hematopoietic cells for multiple myeloma who did not responded after previous high-dose therapyMultiple myeloma
EUCTR2014-000130-37-ITFONDAZIONE NEOPLASIE SANGUE ONLUS (FO.NE.SA. Onlus)73
进行中(未招募)
不适用
A clinical study evaluating the efficacy of topical cromoglicate solution compared to placeboin the treatment of mastocytosisMedDRA version: 15.0Level: PTClassification code 10012812Term: Diffuse cutaneous mastocytosisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 15.0Level: LLTClassification code 10056452Term: Indolent systemic mastocytosisSystem Organ Class: 10005329 - Blood and lymphatic system disordersmastocytosis
EUCTR2011-006275-20-DEEO Pharma A/S
进行中(未招募)
1 期
A Phase II Study to determine the efficacy and safety of conventional dose oral Treosulfan in patients with advanced pre-treated Ewing’s Sarcoma - OTIS
EUCTR2005-003254-10-GBniversity College London25
招募中
2 期
A study on the efficacy and safety of cisplatin/etoposide and concomitant radiotherapy in combination with durvalumab, an immunotherapy, in patients with local limited small cell lung cancer
2024-513433-20-00Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR105
进行中(未招募)
1 期
A randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic, androgen receptor (AR) expressing, salivary gland cancer (SGCs)Salivary gland cancerMedDRA version: 17.0Level: PTClassification code 10061934Term: Salivary gland cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2013-000314-38-FREuropean Organisation for Research and Treatment of Cancer (EORTC)452
Prospective phase IIb study to evaluate the efficacy... | 临床试验